News from Zyme and the companies we work with.

June 18, 19

Owlstone Medical Announces a Novel Approach to Breath-Based Testing for Investigation of the Onset, Progression, and Treatment of Disease

Exogenous Volatile Organic Compound (EVOC®) Probes represent an important advance to support the implementation of Breath Biopsy in a wide range of applications Paper published in peer-reviewed Journal of Breath Research describes the use of EVOCs as metabolic pathway-specific probes … Continue reading →

June 13, 19

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics

Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows Kit developed as part of licensing and supply agreement with Cygnus Technologies Uppsala, Sweden, 13 June 2019: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading … Continue reading →

June 12, 19

Ligand subsidiary Vernalis and PhoreMost Limited announce drug discovery collaboration for novel oncology target

San Diego, USA and Cambridge, UK, 12 June, 2019: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has … Continue reading →

June 10, 19

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

New funding of $2.9 million USD (£2.2 million) is in addition to the $2 million (£1.5 million GBP) investment (announced in January 2019), brings the total raised to $4.8 million USD (£3.7 million GBP) Lead investors were Greenwood Way Capital … Continue reading →

June 10, 19

Avacta Group plc hits clinical candidate selection milestone for Affimer PD-L1 inhibitor  

Selection of its first-time-in-human clinical candidate for the Affimer platform confirmed Group remains on track to submit an IND/CTA application by the end of 2020  Cambridge, UK, 10 June 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics … Continue reading →

June 5, 19

Owlstone Medical and the International Association of Heat and Frost Insulators and Allied Workers Partner to Identify Breath Biomarkers for the Early Detection of Malignant Mesothelioma

Owlstone Medical, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, announced today the formation of a partnership with the International Association of Heat and Frost Insulators and Allied Workers (IAHFIAW), formerly known … Continue reading →

June 4, 19

ERS Genomics licenses CRISPR gene editing technology to Bioneer to further advance preclinical disease modelling

DUBLIN, Ireland, and Hørsholm, Denmark, 04 June, 2019: ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and … Continue reading →

June 3, 19

Avacta Group plc TMAC programme accelerates: clinical trial planned for early 2020

Key linker element of Avacta’s novel TMAC™ drug conjugate to be tested in humans within 12 months Cambridge, UK, 03 June 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that it is planning … Continue reading →

May 28, 19

Expedeon AG adds CaptSure DIY ELISA to immunoassay technology product range

Addressing a billion-dollar market with innovative technologies which remove bottlenecks in research and discovery  Heidelberg, Germany and Cambridge, UK, 28 May 2019 – CaptSure™ DIY ELISA will complement Expedeon AG’s product offering, as the Company (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime … Continue reading →

May 20, 19

Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension

Cambridge, UK, 20 May 2019: Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & … Continue reading →